Axsome Therapeutics, Inc.

DB:19X Stock Report

Market Cap: €4.5b

Axsome Therapeutics Management

Management criteria checks 2/4

Axsome Therapeutics' CEO is Herriot Tabuteau, appointed in Jan 2012, has a tenure of 12.83 years. total yearly compensation is $9.90M, comprised of 7.6% salary and 92.4% bonuses, including company stock and options. directly owns 0.015% of the company’s shares, worth €672.98K. The average tenure of the management team and the board of directors is 6.5 years and 9.9 years respectively.

Key information

Herriot Tabuteau

Chief executive officer

US$9.9m

Total compensation

CEO salary percentage7.6%
CEO tenure12.8yrs
CEO ownership0.01%
Management average tenure6.5yrs
Board average tenure9.9yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Herriot Tabuteau's remuneration changed compared to Axsome Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$311m

Jun 30 2024n/an/a

-US$309m

Mar 31 2024n/an/a

-US$296m

Dec 31 2023US$10mUS$750k

-US$239m

Sep 30 2023n/an/a

-US$202m

Jun 30 2023n/an/a

-US$184m

Mar 31 2023n/an/a

-US$159m

Dec 31 2022US$8mUS$685k

-US$187m

Sep 30 2022n/an/a

-US$160m

Jun 30 2022n/an/a

-US$150m

Mar 31 2022n/an/a

-US$141m

Dec 31 2021US$8mUS$685k

-US$130m

Sep 30 2021n/an/a

-US$126m

Jun 30 2021n/an/a

-US$114m

Mar 31 2021n/an/a

-US$100m

Dec 31 2020US$7mUS$575k

-US$103m

Sep 30 2020n/an/a

-US$99m

Jun 30 2020n/an/a

-US$95m

Mar 31 2020n/an/a

-US$90m

Dec 31 2019US$5mUS$435k

-US$68m

Sep 30 2019n/an/a

-US$53m

Jun 30 2019n/an/a

-US$42m

Mar 31 2019n/an/a

-US$37m

Dec 31 2018US$1mUS$435k

-US$31m

Sep 30 2018n/an/a

-US$29m

Jun 30 2018n/an/a

-US$27m

Mar 31 2018n/an/a

-US$26m

Dec 31 2017US$1mUS$435k

-US$29m

Compensation vs Market: Herriot's total compensation ($USD9.90M) is above average for companies of similar size in the German market ($USD1.92M).

Compensation vs Earnings: Herriot's compensation has increased whilst the company is unprofitable.

CEO

Herriot Tabuteau (56 yo)

12.8yrs

Tenure

US$9,896,629

Compensation

Dr. Herriot Tabuteau, MD founded Axsome Therapeutics, Inc. in January 2012 and has been its Chief Executive Officer, President and Chairman since January 2012. Dr. Tabuteau served as Interim Principal Fina...

Leadership Team

NamePositionTenureCompensationOwnership
Herriot Tabuteau
Founder12.8yrsUS$9.90m0.015%
€ 673.0k
Nick Pizzie
Chief Financial Officer6.5yrsUS$3.57m0.087%
€ 3.9m
Mark Jacobson
Chief Operating Officer9.1yrsUS$4.04m0.012%
€ 538.1k
Hunter Murdock
General Counsel & Secretary2.9yrsUS$3.06m0%
€ 0
Ari Maizel
Chief Commercial Officer1.1yrsno datano data

6.5yrs

Average Tenure

46.5yo

Average Age

Experienced Management: 19X's management team is seasoned and experienced (6.5 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Herriot Tabuteau
Founder12.8yrsUS$9.90m0.015%
€ 673.0k
Roger Jeffs
Independent Lead Director9.9yrsUS$400.34k0.35%
€ 15.6m
Mark Saad
Independent Director9.9yrsUS$405.34k0.021%
€ 958.9k
Susan Mahony
Independent Director1.1yrsUS$417.48k0%
€ 0
Mark Coleman
Independent Director9.9yrsUS$427.84k0.93%
€ 42.1m

9.9yrs

Average Tenure

56yo

Average Age

Experienced Board: 19X's board of directors are considered experienced (9.9 years average tenure).